Press releases

13 November 2013

Verona Pharma to present at Therapeutic Area Partnerships (TAP), Boston, 18-20 November 2013 RPL554 selected as a ‘Top Project to Watch’

13 November 2013, London – Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, announces that it will present at the Therapeutic Area Partnerships (TAP) Meeting, 18-20 November 201…

Read more

25 October 2013

Clinical studies published in The Lancet Respiratory Medicine highlight RPL554 as a promising novel potential treatment for asthma and COPD

Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, announces that a new research paper entitled “Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers a…

Read more

10 September 2013

Clinical data presented at ERS Annual Congress further highlights significant bronchodilator and anti-inflammatory activity of novel dual PDE3/4 inhibitor RPL554

London, UK, 10 September 2013 – Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, announces that two presentations discussing results from successfully completed RPL554 clinical tr…

Read more

5 September 2013

RPL554 Presentations at the European Respiratory Society Annual Congress, Barcelona, Spain 7-11 September 2013

London, UK, 5 September 2013 – Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, announces that two presentations discussing results from successfully completed RPL554 clinical tri…

Read more

1 July 2013

Peer-reviewed paper suggests RPL554 with glycopyrrolate, or other muscarinic receptor antagonists, produces synergistic bronchodilation

Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, announces that a paper entitled “The effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth…

Read more

24 June 2013

First patient dosed in clinical trial to further evaluate efficacy of VRP700 as a treatment for chronic severe cough

Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, today announces that the first patient in a clinical trial to further evaluate the efficacy of VRP700 as a novel treatment for chroni…

Read more

17 May 2013

To present clinical and pre-clinical data highlighting the significant bronchodilator activity of novel dual PDE3/4 inhibitor RPL554 at upcoming ATS international conference

Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, today announces that three posters will be presented at the upcoming annual American Thoracic Society (ATS) International Conference, Phil…

Read more

26 March 2013

Further clinical data highlighting the significant bronchodilator activity of novel dual PDE3/4 inhibitor RPL554 presented at ATS international conference

Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, today announces that a further poster was presented on Tuesday 21 May as part of the scientific programme at American Thoracic Society…

Read more

5 March 2013

RPL554 DEMONSTRATES POSITIVE AIRWAY ANTI-INFLAMMATORY ACTIVITY IN CLINICAL TRIAL

Verona Pharma plc (VRP: London Stock Exchange) ("Verona Pharma", or the "Company"), the biotechnology company focused on developing novel treatments for chronic respiratory diseases today announces the results of an exploratory, placebo-controlled, double-blind clini…

Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us